{"certainAgreement":{"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The trial began on 04 October 2018 with LPLV occurring on 30 March 2022 following Pfizer's strategic decision (not due to any specific safety reasons or request from a regulatory authority) to terminate the study, which included the period during which the COVID-19 pandemic was occurring globally since 11 March 2020."},"pointOfContact":{"email":"ClinicalTrials.gov_Inquiries@pfizer.com","organization":"Pfizer Inc.","phone":"1-800-718-1021","title":"Pfizer ClinicalTrials.gov Call Center"}}